Anthem figures Cigna buy would pass antitrust scrutiny; Viagra no melanoma trigger, data analysis shows;

@FiercePharma: NICE's cost watchdogs favor biosims for RA ahead of Remicade. Story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. FiercePharmaManufacturing feature | Follow @EricPFierce

> As payers gain more power in pharma pricing, big mergers threaten to consolidate the health insurance industry even further, with Anthem confident that its bid for Cigna would pass muster with antitrust regulators. Report

> Viagra doesn't cause melanoma, a new data analysis found, but the lifestyle choices of men who use it and other erectile dysfunction meds could trigger the deadly skin cancer. Report

> Valneva and GlaxoSmithKline ($GSK) ended a marketing deal for the vaccine Ixiaro, with Valneva taking direct control of the product. Report

> Under an Iowa court ruling, doctors could prescribe emergency birth control via video conferencing. Report

Medical Device News

@FierceMedDev: Siemens snags FDA approval for HIV combo test. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: MIT to launch nonprofit focused on empirical evaluation of digital health products. Article | Follow @VarunSaxena2

@EmilyWFierce: Bill Ackman and other philanthropists sink $20M into project @broadinstitute for drug-resistant TB. Article from FierceDiagnostics | Follow @EmilyWFierce

> Broad Institute gets $20M to target TB from Wall Street-led philanthropists. Article

> U.K. NHS spinout Touch Bionics launches smarter, faster, stronger prosthetic hand. Report

Biotech News

@FierceBiotech: Vical shares decimated (again) after herpes vaccine flunks a PhI/II trial. More | Follow @FierceBiotech

@JohnCFierce: Remember that #biotech #IPO pullback we thought we'd see this year? Didn't happen - yet. #blazing. Story | Follow @JohnCFierce

@DamianFierce: Reminder that Chris Viehbacher, now riding high, got ghosted out of lunch by the $SNY board. Image | Follow @DamianFierce

> Clementia bags $60M to push a repurposed Roche drug through Phase II. More

> Avalon leads $17M round for regenerative med biotech Ankasa. Item

Pharma Manufacturing News

> China not only source for counterfeit drugs but also for meth, other synthetics. Report

> Russian company building blood products plant. Item

> Baxter recalling subpotent heparin. Story

> Akorn's Hi-Tech source of another recall. More

> Europe bans some APIs from Chinese drugmaker Zhuhai United. Article

Drug Delivery News

> Bayer studies eye drug delivery in collaboration with Johns Hopkins. Item

> IPOs: Celyad rakes in $100M, Neos shoots for $69M. More

> Harvard team makes 'sweating' vehicles for liquid drug delivery. Story

> Canadian team developing drug-delivering contact lens. Article

> Teva partners with Microchips Biotech to deliver drugs via wirelessly controlled implant. Report

Pharma Asia News

> Asia's emerging biotech scene begs for a look at Kobe, Biocom's Panetta says. More

> Foreign investors allowed up to 44% of India's Syngene IPO shares. Report

> Vietnam gets official WHO nod as global vaccine supplier. Story

> J&J, Stryker, Zimmer in line as India eyes price caps on orthopedic implants. Article

> Package inserts on endoscopes revised in Japan. Item

And finally ... Climate change poses a major threat to human health, potentially able to wipe out major gains over the past 50 years. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.